Table 5.

Treatment-emergent adverse events

	10,000 IU QW (n = 39)	20,000 IU Q2W (n = 76)	20,000 IU Q4W (n = 72)	40,000 IU Q4W (n = 72)
Adverse events in ≥10% of patients in any group, n (%)
diarrhea	4 (10.3)	11 (14.5)	6 (8.3)	8 (11.1)
constipation	4 (10.3)	1 (1.3)	5 (6.9)	1 (1.4)
headache	2 (5.1)	3 (4.0)	5 (6.9)	8 (11.1)
Serious adverse events in ≥2  patients in any group, n (%)
congestive cardiac failure	3 (7.7)	3 (4.0)	1 (1.4)	3 (4.2)
diabetic ketoacidosis	0	0	1 (1.4)	2 (2.8)

QW, once weekly; Q2W, every 2 wk; Q4W, every 4 wk.